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Thrombotic microangiopathies (TMA) are rare but severe disorders, characterized by
endothelial cell activation and thrombus formation leading to hemolytic anemia, throm-
bocytopenia, and organ failure. Complement over activation in combination with defects in
its regulation is described in an increasing number of TMA and if primary for the disease
denominated as atypical hemolytic-uremic syndrome. AlthoughTMA predominantly affects
the renal microvasculature, extra-renal manifestations are observed in 20% of patients
including involvement of the central nerve system, cardiovascular system, lungs, skin,
skeletal muscle, and gastrointestinal tract. Prompt diagnosis and treatment initiation are
therefore crucial for the prognosis of disease acute phase and the long-term outcome.
This review summarizes the available evidence on extra-renalTMA manifestations and dis-
cusses the role of acute and chronic complement activation by highlighting its complex
interaction with inflammation, coagulation, and endothelial homeostasis.
Keywords:TMA, aHUS, complement, extra-renal TMA, neurovascular complications, cardiovascular complication,
gastrointestinal complications
BACKGROUND
Thrombotic microangiopathies (TMA) develop on the basis of
microvascular endothelial cell injury with subsequent forma-
tion of platelet rich microthrombi triggering Coombs negative
hemolytic anemia (except for pneumococcal hemolytic-uremic
syndrome), non-immune thrombocytopenia, and organ failure
(1, 2). The underlying histological lesion is characterized by
prominent endothelial cell swelling and detachment with sub-
endothelial debris, thickened arteriole and capillary walls, and
thrombosed vessel lumina (1, 2).
Under normal conditions, intact endothelial surfaces are resis-
tant to complement activation and are non-thrombogenic (3–5).
The endothelial glycocalyx is the first barrier of the vascular wall
and thus in direct contact to the vessel lumen and is crucial for
endothelial integrity by acting as mechanosensor and permeability
Abbreviations: AAV, antinuclear antiobody-associated vasculitis; ADAMTS13, a
disintegrin and metalloproteinase with a thrombospondin type 1 motif member
13; aHUS, atypical HUS; ANCA, antinuclear antibodies; AP, alternative comple-
ment pathway; APS, anti phospholipid syndrome; CFH, complement factor H;
CFH-Ab, complement factor H antibodies; CFHR, complement factor H related
protein; CFI, complement factor I; CK, creatinine kinase; CMV, cytomegalovirus;
CNI, calcineurin inhibitor; CNS, central nervous system; CP, classical comple-
ment pathway; FFP, resh frozen plasma; HD, hemodialysis; HSCT, hematopoietic
stem-cell transplant; HUS, hemolytic-uremic syndrome; IDDM, insulin-dependent
diabetes mellitus; LP, lectine complement pathway; MBL, mannose-binding lectine;
MCP, membrane-cofactor protein; MRI, magnetic resonance imaging; MRI/A, MRI
angiography; PDGF, platelet derived growth factor; PE, plasmaexchange; PI, plasma
infusion; PRES, posterior reversible encephalopathy syndrome; SLE, systemic lupus
erythematodes; sTNFR1, soluble tumor-necrosis-factor receptor 1; sVCAM-1, sol-
uble vascular cell adhesion protein 1; TA-TMA, transplant-associated thrombotic
microangiopathy; TCC, terminal complement complex; TMA, thrombotic microan-
giopathy; TTP, thrombotic thrombocytopenic purpura; VEGF, vascular endothelial
growth factor; vWf, von-Willebrand-factor.
barrier in addition to its important role in anti-thrombotic and
anti-inflammatory pathways (3, 4). It was shown that endothelial
surface glcocalyx with its heparane sulfates is crucial for the regu-
latory potential of the complement regulator factor H (CFH) and
of proteins involved in the coagulation cascade (3, 6–11). Thus, it
is hypothesized that vascular glycocalyx heterogeneity could serve
as a potential modifier of complement-mediated TMA (3).
Endothelial cells and their secretion products are tightly linked
to the coagulation, fibrinolysis, and complement cascades. Prosta-
cyclines, von-Willebrand-factor (vWF), thrombomodulin, nitric
oxide, tissue plasminogen activator inhibitor, and further more
lead to the loss of endothelial thromboresistance and wide-
spread platelet aggregation creating a cycle of vasoconstriction
and further thrombus formation (2, 3, 5).
The complement system forms an autonomous part of innate
immunity and is essential for the mediation and concertation of
inflammatory reactions, protection against invading organisms,
and thus maintenance of tissue homeostasis (12, 13). The com-
plement system consists of multiple proteins, acting in a cascade
like manner to eliminate foreign invaders. During the activation
process, inflammatory peptides are cleaved from inactive pro-
teins (zymogenes) exerting multiple biological functions. Three
activation pathways, the classical (CP), the lectin (LP), and the
alternative pathway (AP) converge in the production of the“mem-
brane attack complex” or “terminal complement complex” (TCC)
(14–16). Binding of C1 (composed of a recognition unit, C1q, and
a tetramer of the zymogens C1r and C1s) to an activator (mainly
immunocomplexes) is the initial step leading to CP complement
activation (14–16). Mannose-binding lectins (MBL) and ficolins,
which are capable to bind on specific surfaces of microorganisms
or dying cells, initiate complement activation via the LP (14–16).
The AP is initiated spontaneously by unspecific C3 hydrolysis
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leading to a constant C3b production with covalent deposition
onto plasma exposed surfaces. On foreign surfaces, e.g., bacterial
surfaces, C3b triggers the activation of the AP. Without regulation,
even small triggers can lead to a self-preserving amplification of
the AP with consumption of the complement components and a
harmful response against “self”-surfaces (14–16).
On the host cells, this cascade is controlled by membrane-
anchored (membrane-cofactor protein (MCP), complement
receptor 1, decay accelerating factor, CD55 and CD59), and fluid
phase regulators (C1 inhibitor, C4 binding protein, CFH, comple-
ment factor I (CFI), CFH related proteins 1–5 (CFHR 1–5), clus-
terin, and vitronectin) (14–16). Foreign targets and injured cells
that lack these regulators are attacked by complement, forming the
TCC into the cells membrane leading to its lyses.
Complement-mediated TMA and especially atypical hemolytic-
uremic syndrome (aHUS) are linked to uncontrolled activation of
the AP (1, 2, 13):
Mutations in complement proteins (CFH, MCP, CFI, comple-
ment factor B (CFB), C3, or thrombomodulin) as well as anti-
bodies against complement factor H (CFH-Ab) can be found in
around 60–70% of patients with aHUS (1, 2). However, similar
complement alterations were detected in ∼30% of patients with
de novo post-renal-transplant HUS, 70% with recurrent HUS after
kidney transplantation, and in one patient with severe TMA and
antibody-mediated rejection (1, 2). Moreover, complement alter-
ations and mutations are detected in 86% (18/21) of patients with
pregnancy-associated HUS, in 43% (3/7) patients with cobalamin
C deficiency, and in TMA associated with hematopoietic stem-cell
transplantation (HSCT) (1, 2). Complement protein variants and
mutations were also anecdotally reported in patients with TMA
associated with ticlopidine, cisplatin, and carboplatin as well as
malignant hypertension (MH) (1, 2). Thus, patients with underly-
ing complement-regulatory defects have an increased propensity
to develop TMA upon trigger events.
In general, the question why the glomerular endothelium is
the main target of TMA is still unsolved. It is speculated that the
specific fenestration of the glomerular endothelial cells leads to a
higher susceptibility to complement activation and makes it more
vulnerable to complement dysregulation as the glomerular base-
ment membrane lacks surface bound complement regulators (2,
4, 12, 17). Moreover, the glomerular endothelial cell was shown to
depend on vascular endothelial growth factor (VEGF) produced
and secreted by podocytes allowing vascular endothelial regener-
ation and maintaining endothelial health (4, 18) (Figure 1). Thus,
considering extra-renal TMA manifestations with endothelial dys-
function and injury in a more “protected” surrounding a higher
cumulative endothelial stress potential may be needed to induce
TMA as compared to the more vulnerable renal microvasculature.
Considering those hypothesis, one may conclude that in addition
to endothelial stress factors the level and quality of endothelial
protective factors like nitric oxide production and VEGF secretion
may modulate TMA pathogenesis and thus renal and extra-renal
TMA manifestations.
A big player leading to endothelial stress is complement dys-
regulation and activation on cell surfaces, additionally triggered
and stimulated by different infections and toxins (shigatoxin,
neuraminidase) (4, 12, 17).
Although complement-mediated TMA predominantly affects
the renal microvasculature, extra-renal TMA manifestations are
observed in up to 20% of patients including involvement of the
central nerve system (CNS), cardiovascular system, lungs, skin,
skeletal muscle, and gastrointestinal tract (1, 2, 12, 19, 20). Those
extra-renal complications may not only be observed during dis-
ease acute phase but can also manifest to some degree years after
it (1, 2, 12, 19, 20) and are thought to result from a chronic
over activation/dysregulation of the complement system, on the
basis of an altered endothelial cell integrity with a predominance
of anti-protective and potentially endothelial cell damaging fac-
tors (inflammation, drugs, hypertension, radiation, complement
activation, etc.) (Figure 1) (2, 4, 12, 20).
In this review article, we discuss the role of acute and chronic
complement activation and dysregulation with respect to the
spectrum of extra-renal TMA complications.
CEREBROVASCULAR TMA MANIFESTATIONS
Central nerve system involvement is the most frequent extra-renal
organ manifestation of aHUS (10–48%) (1, 2, 20–24). Symptoms
are heterogeneous including irritability, drowsiness, convulsions,
encephalopathy, diplopia, cortical blindness, hemiparesis or hemi-
plegia, stupor, and coma (1, 2, 20–24). Thus, CNS involvement
represents a major cause of mortality and morbidity in affected
individuals.
When considering neurological involvement due to complement-
mediated TMA, a differentiation to secondary CNS phenomena
induced by electrolyte dysbalances, uremia, and arterial hyper-
tension is essential. CNS complications due to arterial hyper-
tension [reversible posterior leukoencephalopathy syndrome with
posterior white matter hyper intensity (PRES)] may show sim-
ilar clinical presentations including vision loss and seizures and
both entities may be interrelated in complement-mediated TMA
(1). Moreover, rare CNS manifestations due to steno-occlusive
lesions of the carotid arteries and cerebral lesions due to microvas-
cular TMA lesions have to be differentiated. Interestingly, vas-
cular lesions of large arteries in patients with complement-
mediated TMA (Table 1) are reported mainly in patients with
ESRD on long-term dialysis. The involved arteries are mainly
from the carotid and vertebral arteries leading to ischemic CNS
manifestations.
The clinical presentation of cerebral TMA lesions and sec-
ondary CNS phenomena are often indistinguishable, thus brain
magnetic resonance imaging (MRI) including MRI-angiography
(MRI/A) is essential to differentiate CNS complications due to
arterial hypertension (PRES) and those due to cerebral TMA
and/or steno-occlusive lesions (1, 26, 34, 37).
The following MRI findings are described frequently in the
literature during the acute phase of HUS and are currently inter-
preted as directly TMA-associated lesions (1, 26, 34, 37): symmet-
rical and mainly bilateral basal ganglia, brainstem, and deep white
matter lesions on diffusion weighted imaging.
There is a distinctive similarity of radiologic lesions found
in patients with shigatoxin-HUS and those with aHUS (26, 37–
39), leading to the hypothesis that those lesions are caused by a
microangiopathic, thrombotic processes triggered by endothelial
cell damage due to or in addition to complement dysregulation,
Frontiers in Pediatrics | Pediatric Nephrology September 2014 | Volume 2 | Article 97 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hofer et al. Extra-renal TMA manifestations
FIGURE 1 | Scheme on the pathophysiologic understanding of
extra-renal complement-mediatedTMA manifestations. Endothelial
dysfunction and injury represent the center of TMA pathogenesis.
Different endothelial harming factors can lead to endothelial
dysfunction. Especially on the basis of inherited or acquired defects of
complement regulation and activation, those factors can lead to severe
complement activation inducing widespread endothelial injury with the
consequence of local and systemic activation of inflammation and
coagulation. All these complex complement concerted and maintained
processes may finally lead to vasculopathy of microvessels including
vasa-vasorum with large artery stenosis and organ ischemia followed
by multiple renal and extra-renal symptoms. C3a, complement
component 3a; C5a, complement component 5a; CMV,
cytomegalovirus; CNI, calcineurin inhibitor; CNS, central nerve system;
EBV, Epstein–Barr virus; e.g., exempli gratia; EHEC, enterohemorrhagic
Escherichia coli ; H1N1, influence A virus subtype; m-TOR, mammalian
target of rapamycin; TCC, terminal complement complex; TMA,
thrombotic microangiopathy.
which is not only a key feature in aHUS but also in shigatoxin-
HUS (40, 41).
Interestingly, even in patients with severe CNS involvement
on acute imaging, progression, and clinical development was
favorable for basal ganglia lesions (in those studies no differen-
tiation between shigatoxin-HUS and aHUS was/could be made)
(38, 39). In contrast, detection of hemorrhagic CNS lesions is
associated with at least minor neurological dysfunction on the
long-run or delayed neurological recovery (38, 39). In the case
of recurrent aHUS, MRI findings can distinguish those TMA-
associated CNS manifestations from secondary CNS involvement
(e.g., hypertensive encephalopathy) with important implications
on the further management of those patients (26).
The largest aHUS cohorts describe cerebrovascular complica-
tions due to aHUS onset in 5/45 (11%; 1 CFH, 1 CFI, 3 without
known mutation) (24), 23/211 (11%; 5 CFH, 2 CFI, 1 C3, 1
CFH-Ab, 14 without known mutation) (23), 6/45 (13%; 1 C3,
1 CFB, 1 CFH-Ab, 3 without known mutation) (21), and 11/23
(48%; no genotyping) (22) patients. Cohort studies on patients
with CFH-Ab HUS (42) describe CNS involvement in 56/138
(41%) (43), 8/32 (23.5%) (44), and 2/19 (11%) (45). In addition,
there are a number of case reports on patients with distinc-
tive TMA CNS manifestations (25–29, 46) and steno-occlusive
vascular CNS manifestations (30–36) (Table 1). As reported by
Koehl et al. (26), recurrence of aHUS can present as isolated CNS
manifestation without laboratory signs of complement activation.
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Table 1 | Overview of case reports describing cerebrovascular CNS manifestations (CNS,TMA, and macrovascular CNS manifestations).
Reference Age onset/sex Defect Characteristics Imaging/biopsy results Specific therapy Outcome
CNSTMA
(25) 19 months/f CFH -Polym aHUS onset with fluctuating level of
consciousness, prolonged, generalized,
tonic–clonic seizures, hemiparesis; EEG showing
diffuse slow-wave encephalopathy; In addition
cardiovascular instability with poorly contractile left
ventricle and a LV-EF of 30%
MRI: subtle bilateral parenchymal
abnormalities
Eculizumab started
within 12 h after
diagnosis
Subtle weakness in right-thumb and
finger otherwise age adequate
neurologic investigations
(26) 4 years/m CFH/CFHR1 Despite intense PT ESRD 8 months after onset;
1 month thereafter bilateral nephrectomy due to
uncontrolled hypertension; 3 days after
nephrectomy sudden onset of partial complex
epileptic seizures without laboratory signs of aHUS
recurrence and with normal blood pressure;
1 month thereafter recurrence of generalized
seizures; 8 months later third episode of seizures
with decreased hemoglobin, low haptoglobine, and
moderate thrombocytopenia; persistent deep
confusion and violent agitation over 2 days
First MRI (at onset of CNS
symptoms): normal; Second MRI:
normal; Third MRI: bilateral
symmetrical hyperintensities on
cerebral pedunculas, caudate nuclei,
putamens, thalami, hippocampi,
and insulae; fourth MRI (after
initiation of PT): completely normal
After third episode
of CNS symptoms
with MRI lesions
suggestive for TMA
start with intense
PE and after
4 weeks PE
replaced by PI
Normal clinical examination except
for high blood pressure
(27) 50 years/f n/a During first disease flair (day three) unresponsive
seizures; EEG: diffuse cerebral dysfunction
Initial CT: unremarkable, MRI
28 days after Eculizumab start:
subacute right parietal lobe
infarction with areas of hemorrhagic
conversion; suspected tiny
subacute infarct within the right
cenrtum semiovale
Eculizumab started
at day 6 after
disease onset
Complete neurologic (and renal)
recovery
(28) 11 years/f CFH -Polym,
CFI-Mut.
Partial response to PI and PE; multiple tonic–clonic
seizures despite ongoing PE therapy; 2 days after
first seizures vision loss and severe confusion;
laboratory investigations showed hemolysis and
thrombocytopenia
First MRI: bilateral, symmetrical
hyperintensities on the occipital and
posterior parietal lobes and edema;
second MRI (2 months therafter):
normal
Prior to CNS
manifestation PT;
thereafter
eculizumab in
addition to
levetiracetam
Complete neurologic recovery after
1 month; normalization of MRI
(Continued)
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Table 1 | Continued
Reference Age onset/sex Defect Characteristics Imaging/biopsy results Specific therapy Outcome
6 years/f MCP-Mut. Initially response to PE and HD with a clear
hematologic response after 5 days; on day six
patient developed tonic–clonic seizures, followed
by vision loss and nystagmus – in parallel
worsening hemolysis and thrombocytopenia
MRI: bilateral, hyperintense white
matter lesions in the occipital and
posterior parietal regions
Eculizumab was
initiated after MRI
Five weeks after first eculizumab
dose complete neurologic,
hematologic, and renal recovery
(29) 25 years/m De novo
TA-TMA
Ktx at 12 years of age due to FSGS; uneventful
course till age of 25 years; at 25 years acute onset
of left-sided weakness preceded by general fatigue
and progressive forgetfulness in the previous
2 months. Lab at time of admission showed mild
thrombopenia, with low normal hemoglobin, and
LDH
First MRI/A: right-sided
temporo-parietal and thalamic
lesions; missing flow signal of the
right middle cerebral artery; second
MRI/A: additional ischemic lesions
of the left-sided thalamus and both
occipital regions; Brain biopsy:
extensive necrosis and arteriolar
hyalinosis; Post-mortem
examination: disseminated TMA of
brain, lungs, and renal allograft
Cyclosporin A,
prednisolone,
valsartan, and
darbepoetin alpha
at time of CNS
manifestation; no
specific TMA
therapy
After first MRI/A the patient was
discharges with ASS; 4 weeks later
admission due to listlessness and
mutism; 5 days thereafter bilateral
blindness was discovered and
Cyclosporin A was paused; second
MRI/A was performed;
development of severe arterial
hypertension, rapidly declining
platelets and slightly increased
LDH; C3/C4 and CH50 normal, no
further complement analyses
MACROVASCULAR CNS MANIFESTATIONS
(30) 20 months/f Fam. At diagnosis development of gangrenous lesions of
finger and toes with thromozytopenia, increased
LDH, fragmentocytes, and creatinine; 90 days after
aHUS onset seizures and acute hemiparesis
First MRI/A: ischemia of the right
frontoparietal region and
steno-occlusive lesions of both
internal carotid arteries and patent
vertebral arteries; no laboratory
signs of TMA
After aHUS onset
16 PE sessions and
four PI leading to
aHUS recurrence
n/a
(31) 4 years/f Stx-HUS Stx-HUS onset with ESRD and need for PD.
3 months after onset various neurologic complaints
including tonic movements of the left limbs,
transient vision loss, and intermittent dysarthria
MRI/A: acute infarction in the right
middle cerebral artery territory with
bilateral occlusions of the distal
internal carotid arteries with
multiple small collaterals similarly to
moyamoya disease; C3, C4, CH50,
and CFH concentration normal, no
further complement studies
performed
PD;
revascularization
surgery;
Planed for renal transplantation;
after revascularization persistent
mild hemiparesis
(Continued)
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Table 1 | Continued
Reference Age onset/sex Defect Characteristics Imaging/biopsy results Specific therapy Outcome
(32, 33) 3 years/f CFH-mut;
fam.
Acute onset of aHUS proceeding to ESRD – first Ktx
with aHUS recurrence and subsequent graft loss on
day 3; nephrectomy was performed; with 12 years
second Ktx under prophylactic pre and
post-transplant PE. Eight weeks later creatinine
increase and intense TMA lesions on biopsy, despite
intensive PE graft loss and patient on HD. With
15 years episodic sensory and motor
symptoms – first MRI; with 17 years third Ktx under
prophylactic pre and post-transplant PE;
postoperatively infarction in the right frontoparietal
region with left-sided hemiparesis, focal seizures,
and impaired consciousness. Thereafter progressive
neurologic recovery without additional events under
PE. Later on PE was switched to Eculizumab
First MRI/A: severe stenosis in
proximal segments of the middle
and anterior cerebral arteries;
Further imaging: infarcts in the right
frontal and frontoparietal regions
Prophylactic PE and
later on due to allergic
reactions Eculizumab
Progressive recovery of
neurologic symptoms under PE
(34) 1 month/f CFB-mut. aHUS with ESRD at 4 months; due to severe arterial
hypertension bilateral nephrectomy at the age of
1 year. Ktx at the age of 19 months; 15 days
thereafter hematologic recurrence, treated with PE
and IVIG. With 6 years again HD dependent,
nephrectomy of the graft; with 10 years episodes of
bilateral hemiparesis and loss of consciousness.
Imaging studies showed multiple and intense
stenoocclusive vascular lesions cerebral, pulmonal
cardial and peripheral
MRI/A: bilateral stenosis of
intracranial carotid arteries and left
subclavian and vertebral arteries;
CT-Angiography and cardiac
catheterization: stenosis of all
branches of pulmonary arteries,
moderate pulmonary arterial
hypertension and stenosis of distal
anterior interventricular, right and
marginal coronary arteries, right
humeral artery, celiac trunk and
splenic artery
Initially HD and
nephrectomy.
Recurrence after 1st
transplant treated
with IVIG and PE.
After graft loss
nephrectomy and
again HD. After onset
of cerebrovascular
symptoms attempt of
carotid siphon
angioplasty
Attempt of carotid siphon
angioplasty, complicated by
dissection and massive infarction
leading to death
(35) 2 month/m C3-mut. Ten months after recovery of aHUS fulminant
recurrence with ESRD despite PE. After 4.5 years PD
and poor blood pressure control sudden onset of
convulsions involving the right hand and face,
followed by hemiparesis and aphasia (at that time
normal RR and normal lab); MRI/A revealed
stenoocclusive lesions; symptoms resolved
completely without specific therapy; 1 year
thereafter Ktx under prophylactic eculizumab
therapy. At day four seizures of the right hand and
face and aphasia; death at day 9 after transplantation
MRI/A: stenosis of the left internal
carotid artery and bilateral
collaterals of the middle cerebral
arteries; signs of subacute stroke in
the territory of the left middle
cerebral artery. CT after renal Tx:
massive ischemic lesions in the
region of the middle cerebral
arteries
PE after first
recurrence – ESRD –
PD – transplantation
under prophylactic
eculizumab
Development of severe stroke
on day 4 after Ktx leading do
death within 5 days despite
eculizumab therapy
(Continued)
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Table 1 | Continued
Reference Age onset/sex Defect Characteristics Imaging/biopsy results Specific therapy Outcome
(36) 17 months/f CFB and
CFI mut. in
addition to
CFH-polym
Despite intensive PE ESRD 3 month after aHUS
onset; with 3 years Ktx under prophylactic
post-transplant PE and PI and nephrectomy of
native kidneys. Despite prophylactic PT three aHUS
recurrences leading to malignant hypertension and
generalized seizures with transient focal neurologic
symptoms (normal CT); with 4 years transplant
nephrectomy and HD, PT was terminated. Seven
years later, despite normal laboratory parameters
development of a transient ischemic attack with
severe neurological symptoms including vomiting,
headache, aphasia, ataxia, confusion and
weakness in both arms; measurement of C3 and
C3dg showed ongoing complement activation and
eculizumab was initiated under the suspicion of
complement-mediated TMA like vasculopathy; Ktx
11 months after the TIA episode
CT at onset of CNS symptoms:
normal, MRI/A at second severs
CNS manifestation: total occlusion
of the right carotid artery and
near-occlusion of the left carotid
artery. Repeated imaging over a
period of one year showed no
progression of vascular occlusions
under eculizumab therapy
Eculizumab was
started after severe
TIA episode
Repeated imaging over a period of
one year showed no progression of
vascular occlusions under
eculizumab therapy. The patient was
successfully re-transplanted under
eculizumab
aHUS, atypical hemolytic-uremic syndrome; CFB, complement factor B; CFH, complement factor H; CFHR, CFH related protein; CFI, complement factor I; CNS, central nerve system; CT, computer tomography;
EEG, electroencephalogram; ESRD, end stage renal disease; f, female; fam., familial; FSGS, focal segmental glomerulosclerosis; HD, hemodialysis; IVIG, intravenous immunoglobulins; Ktx, kidney transplantation;
LDH, lactate dehydrogenase; LV-EF, left ventricular ejection fraction; m, male; MCP, membrane-cofactor protein; MRI, magnetic resonance imaging; MRI/A, MRI angiography; Mut., mutation; n/a, not available; PD,
peritoneal dialysis; PE, plasma exchange; PI, plasma infusion; Polym., polymorphism; PT, plasma therapy (PE and/or PI); Stx, shigatoxin, TIA, transient ischemic attack; TMA, thrombotic microangiopathy.
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Patients with intracerebral TMA manifestations responded to early
therapy [plasma exchange (PE) and/or eculizumab] in a signifi-
cant proportion, while patients with macrovascular involvement
showed diverse outcomes from response to PE/eculizumab up to
death despite intensive eculizumab treatment (Table 1). However,
early therapeutic interventions seem to be essential for a positive
outcome.
CARDIOVASCULAR TMA MANIFESTATIONS
Cardiovascular complications have been reported in about 10% of
aHUS patients including cardiomyopathy, myocardial infarction,
myocarditis, and heart failure as well as steno-occlusive coronary
lesions (1, 20–24). Again, the differentiation between primary
complement-mediated, TMA-associated defects and secondary
phenomena due to volume overload and/or arterial hypertension
is essential but not always clear.
Table 2 summarizes the available case reports on patients with
complement-associated cardiovascular TMA manifestations (34,
47, 48). In addition to those detailed case reports, several cohort
studies on aHUS describe cardiac manifestations:
Neuhaus et al. (22) report on heterogeneous clinical presen-
tations of aHUS, describing 10 children with cardiomyopathy at
discharge, two of them died, no genotyping was available. Ven-
ables et al. (49) describe eight patients with familial aHUS on the
basis of a CFH/CFHR1 hybrid gene, one of those patients died
of myocardial infarction 10 years after aHUS onset, another died
of cardiac arrest 8 weeks after onset. In a cohort study on spo-
radic and familial aHUS, Noris et al. (23) investigated 273 aHUS
patients (adults and children). Out of those, seven patients were
documented as having cardiovascular disease during acute aHUS
episodes, five of those with identified CFH mutations. In a cohort
study of 45 patients with CFH-Ab-associated aHUS (44),3 patients
were described developing cardiac insufficiency on the long-run,
one of them died. Analog, out of seven children with CFH-Ab-
associated aHUS one died due to myocarditis (50). Roumenia et al.
(51) report on 14 aHUS patients with C3 mutations, 7 patients had
dilated cardiomyopathy, 5 during acute phase, 1 of those died at
onset following a cardiovascular event.
In one case report (47), histological work up after necroscopy
in a 43-year-old woman with CFH mutation caused aHUS and
cardiac arrest was performed. The histology revealed TMA fea-
tures of the small coronary vessels with intense TCC staining in
the small vessels and infarcted cardiomyocytes.
Thus, especially patients with genetic or acquired CFH and C3
defects appear to be at highest risk for cardiac complications due
to microangiopathic injury in the coronary microvasculature (20).
Interestingly cardiac involvement is described in a significant
percentage of patients with thrombotic-thromboytopenic pur-
pura (TTP) (52, 53), a disease entity characterized by “a dis-
integrin and metalloproteinase with a thrombospondin type 1
motif member 13”(ADAMTS13) protease deficiency related TMA.
In autopsy studies, those patients presented evidence for cardiac
TMA in 84% of the patients (53). In spite of these pathologic
observations, cardiac symptoms and clinical cardiac abnormalities
are rarely described in those patients. Although complement-
mediated TMA represents a distinct disease entity than TTP,
there are several similarities. The author of a systematic review
on cardiac involvement in TTP concluded that the discrepancy
between clinical and pathologic cardiac abnormalities may be due
to under diagnoses of cardiac involvement, as the common symp-
toms of dyspnea and weakness may be primarily attributed to
anemia and cardiac symptoms may also be overlooked because
many patients are young and without cardiac risk factors (52).
The same conclusions seem reasonable for complement-mediated
TMA were only few studies have investigated cardiac involve-
ment, although the limited data suggest cardiac involvement as
an important cause of continuing mortality.
A study on the incidence and prognosis of acute heart failure
in adult patients with TMA in general (54) found an acute heart
failure prevalence of 9.5%. The incidence of acute heart failure
did not differ between idiopathic and defined causes of TMA.
Patients with heart failure experienced around twice the mortality
of patients without heart failure despite receiving PE therapy. In
surviving patients, left ventricular systolic function improved over
time. Nevertheless, no complement studies were performed.
There are also a number of case reports on cardiac compli-
cations in shigatoxin-HUS (55–63) with outcomes varying from
complete recovery, over stabile improvement till death (dilata-
tive cardiomyopathy in five patients, myocardial infarction in one
patient, myocarditis in two patients, tamponade in two patients).
Altogether, 7 aHUS patients with CFH mutations, 4 with CFH-
Ab aHUS, 2 with a CFH/CFHR1 hybrid gene, 7 with C3 mutations,
1 with a CFB mutation, and 12 without a known mutation or with-
out genotyping are described with cardiovascular events may be
related to complement TMA. Thus, systemic screening for cardiac
symptoms and manifestations are necessary and recommended
on a regular basis for any patient with TMA, especially those with
high risk mutations (Figure 2).
As detailed initially and in the discussion section, endothe-
lial damage is at the center of TMA pathogenesis and cumula-
tive endothelial harming factors may lead to smoldering TMA
processes in several organs. Especially in the setting of renal and
further organ transplantation on the basis of inherited or acquired
complement-regulatory defects in combination with the comple-
ment activating potentials of the surgery and the further endothe-
lial harming effects of several immunosuppressive drugs, especially
calcineurin-inhibitors (CNI) and m-Tor inhibitors (Figure 1),
extra-renal TMA, and thus cardiovascular manifestations earn
increased attention. In a French study including 57 aHUS patients
who had received a kidney transplant 7% died following cardio-
vascular events, two due to myocardial infarction, one due to acute
cardiac failure, and one due to extensive stroke (64). As all patients
were lacking major cardiovascular risk factors, endothelial lesions
with TMA and the micro- and macrovasculature are the most
plausible explanation (64).
Malignant hypertension is known to cause and/or trigger TMA
(2). As detailed initially, complement-regulatory defects are found
in a significant percentage of patients with MH and TMA. How-
ever, TMA may also cause MH, thus in patients with unexplained
MH and any additional sign of TMA (hemolytic anemia, throm-
bocytopenia, renal failure, multiorgan damage) one has to con-
sider a complement-mediated TMA process and complement
screening at least on a functional basis is recommended to be
performed.
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Table 2 | Overview of case reports on cardiovascularTMA manifestations in aHUS.
Reference Age at onset/sex Defect Characteristics Imaging/biopsy results Specific therapy Outcome
CARDIALTMA
(34) 1 month/f CFB-mut. Anephric patient (Ktx; aHUS recurrence, graft
loss, nephrectomy) with sudden onset of
neurovascular symptoms (further details see
Table 1)
CT-angiography and cardiac catheterization:
stenosis of all branches of pulmonary
arteries, moderate pulmonary arterial
hypertension, and stenosis of distal anterior
interventricular, right and marginal coronary
arteries, right humeral artery, celiac trunk,
and splenic artery
After onset of
cerebrovascular
symptoms attempt of
carotid siphon
angioplasty
Attempt of carotid siphon
angioplasty, complicated
by dissection and massive
infarction leading to death
(48) 1 year/f CFH-mut. PE and HD after aHUS onset, ongoing
hemolysis and severe hypertension. Two
months after disease onset with worsening
proteinuria, arterial hypertension, renal
insufficiency, anemia, thrombopenia, and
dilated cardiomyopathy leading to
cardiorespiratory arrest with subsequent
resuscitation and mechanical ventilation;
under ongoing PE the clinical condition
slightly improved but cardiac dysfunction did
not resolve; thus eculizumab was introduced
On echocardiography signs of
cardiomyopathy; ejection fraction
decreased (around 31%)
PE leading to slight
improvement of cardiac
function; after
introduction of
eculizumab
normalization of cardiac
function
Normalization of cardiac
function
(47) 43 years/f CFH-mut; fam Onset of aHUS including nephrotic syndrome
and pulmonary edema with low C3; kidney
biopsy showed typical TMA lesions. PE led to
hematologic recovery. On day 15 after
beginning of PE the patient developed
sudden circulatory arrest with pulse rates
under 25/min and the patient died despite
immediate resuscitation attempts
Cardiac ultrasound during circulatory arrest:
pericardial effusion with tamponade;
Necroscopy: myocardial infarction without
obstruction of the coronary arteries;
multiple microscopic cardiomyocyte
necrosis were present; no coronary
thrombi or atherosclerosis; the small
vessels showed microscopic features of
TMA; immunochemistry revealed activation
of final pathway of complement
PE leading to
hematology remission
Sudden cardio circulatory
arrest at day 15 of PE
followed by death
aHUS, atypical hemolytic-uremic syndrome; CFB, complement factor B; CFH, complement factor H; CT, computer tomography; f, female; fam., familial; HD, hemodialysis; Ktx, kidney transplantation; m, male; MRI,
magnetic resonance imaging; MRI/A, MRI angiography; Mut., mutation; n/a, not available; PD, peritoneal dialysis; PE, plasma exchange; PI, plasma infusion; PT, plasma therapy (PE and/or PI); TMA, thrombotic
microangiopathy.
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FIGURE 2 | Recommendation for evaluation and monitoring of
extra-renal manifestations in patients with complement-mediatedTMA.
Depending on the clinical presentation and possible symptoms, the
physicians have to be aware of TMA associated, potentially devastating
extra-renal TMA manifestations. A high level of suspicion may be needed to
diagnose and treat those complications early in disease course. Thus, the
initial laboratory and imaging investigations as well as the monitoring
procedures have to reflect this knowledge. However, the indications for highly
invasive diagnostic procedures like heart catheterization and MRI/A in small
children with the need of total anesthesia have to be proven on an individual
basis. The recommendation for MRI/A 2 years after onset in all patients with
complement-mediated TMA excludes children with the need for total
anesthesia, except those with clinical cerebrovascular symptoms. ALAT,
Alanin-aminotransferase; AP, alkaline phosphatase; ASAT,
aspartat-aminotransferase; CK, creatine kinase; ECG, electrocardiography;
ECHO, echocardiography; EEG, electroencephalography; gamma-GT,
gamma-glutamyl transpeptidase; MRI/A, magnetic resonance
imaging/angiography; nt-pro-BNP, N-terminal pro brain natriuretic peptide.
The scarce data on therapy and outcome of cardiac and car-
diovascular TMA do not allow any clear conclusions; neverthe-
less, as for cerebrovascular TMA late diagnosis and late initia-
tion of PE and/or eculizumab seems detrimental for the further
development.
PERIPHERAL VASCULAR AND SKIN TMA MANIFESTATIONS
Gangrenous lesions of finger and toes are reported for only six
children with aHUS in three independent case reports (30, 65, 66).
In four out of six patients complement investigations were per-
formed. Four showed decreased C3 levels. For only two of the six
patients further genetic screening and antibody analyses are avail-
able, one showing a C3 mutation and the other one presenting
with CFH-Ab:
A 4-year-old girl with CFH-Ab aHUS and decreased C3 lev-
els developed gangrenous lesions of the fingers 2 days after aHUS
onset. The patients unfortunately died 3 weeks later due to dialysis
related complications (65).
Another child with a C3 mutation and decreased C3 levels
showed aHUS onset at the age of 4 months. Five months later,
she developed ischemic changes in fingers and toes progressing to
gangrenous lesions despite intensive PE. Nevertheless, after initia-
tion of eculizumab all left non-necrotic lesions regained perfusion
wile aHUS activity subsided (65).
A 3-year-old boy presented with aHUS and decreased C3 lev-
els. He was treated with fresh-frozen-plasma (FFP) infusions.
As he developed ischemia of fingers and toes, PE was started
but the ischemic lesions progressed to gangrenous and necrotic
lesions, which had to be removed in the fourth month after disease
onset (66).
Three further patients aged 20 months, 28 months, and 7 years
at age of aHUS diagnosis developed gangrenous lesions of
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fingers. In one patient recovery of the lesions following PE was
noticed. One patient showed additional carotid artery thrombosis
after recovery from aHUS. The third patient died due to lack of
appropriate therapy of uremia (30).
Notably, all patients reported with peripheral gangrenous
lesions were children with severe forms of aHUS. Those reports
lead to the suggestion that under certain conditions (including
pro and anti-protective factors for endothelial cell function) TMA
lesions can additionally affect small-medium arteries [luminal
diameter of digital arteries about 100-fold larger than of the typi-
cally affected glomerular arteries (20)]. The low C3 levels and the
further complement system anomalies (CFH-Ab, C3 mutation)
further strengthen the hypothetic role of uncontrolled activation
of the AP of complement in the pathogenesis of the described
gangrenous lesions.
Skin involvement is a rare but maybe under diagnosed com-
plication in the context of complement-mediated TMA and is
reported for three patients in the literature. Ardiassino et al. (67)
describe three cases of complement-mediated aHUS, two with
a CFH mutation and one with CFH-Ab HUS, who developed
skin lesions that completely recovered after establishing PT or
eculizumab.
The macroscopic picture of all three patients with the clear
diagnosis of aHUS was similar and compatible with a cutaneous
small-vessel vasculopathy potentially induced by a complement-
mediated TMA. In addition, the skin histology of the only patient
who underwent biopsy was compatible with TMA. Moreover, there
was a clear and impressive response to PT or eculizumab. None
of the patients showed laboratory signs of aHUS activity. Thus,
any skin lesion of unknown origin in patients with TMA should
be considered as possible TMA manifestation despite laboratory
signs of disease activity and may form an indication for a therapy
with eculizumab or plasmatherapy [PT; PE and/or plasma infusion
(PI)] (67).
TMA AND THE PULMONARY SYSTEM
Clinically, significant pulmonary TMA manifestations are only
anecdotally reported in the literature and mainly in the context of
multiorgan manifestations of severe and fulminant complement-
mediated TMA. Approximately 5% of patients with aHUS present
with a life-threatening multivisceral failure due to diffuse TMA
including cardiac ischemic events, CNS complications, pancre-
atitis, intestinal bleeding, hepatic cytolysis, rhabdomyolysis, and
pulmonary hemorrhage and failure. In those studies, post-mortem
analysis revealed diffuse TMA lesions (1, 23, 24).
Abdallah et al. (68) report on a patient with acute renal failure
and pulmonary hemorrhages. Kidney biopsy showed TMA and
after prednisolone pulse and PE the patient recovered. ADAMTS13
activity and detailed complement analytics were not performed.
Losito et al. (69) report on a patient presenting with TMA
of the kidneys and pulmonary hypertension. The patient showed
normocytic anemia, a slightly raised LDH and a borderline C3
together with an increased creatinine and a nephritic syndrome.
Pulmonary hypertension was diagnosed 3.5 years after TMA onset
by echocardiography and heart catheterization. The patient com-
plained of asthenia and exertional dyspnea as well as syncopes. At
the same time, renal function worsened. Treatment with warfarin
and epoprostenol was started, 18 months thereafter bosentan, an
oral endothelin antagonist, was started and prostacyclin treat-
ment discontinued. Under bosentan, the patient improved sig-
nificantly including a stabilization and normalization of renal
function. No further genetic analysis were performed. No further
disease recurrences were documented. As endothelial dysfunction
is one of the key players for TMA development, it is not surpris-
ing that endothelin with its vasoconstrictive potential has been
advocated in TMA (70, 71). Interestingly treatment with bosen-
tan in this patient led to improvement of both, renal function
and pulmonary arterial hypertension. Eighteen years after ini-
tial presentation, this patient was diagnosed with cobalamin C
deficiency, and treatment with hydroxocobalamin was instituted
without significant changes on the clinical condition (72). Of note,
pulmonary hypertension is observed in a significant proportion
of patients with cobalamin C deficiency associated TMA (72).
Although this entity does not present a primary complement-
mediated TMA pathology, it shows that TMA processes within the
pulmonary vasculature may lead to pulmonary hypertension and
should be considered in patients with diagnosed TMA as possi-
ble underlying mechanisms for otherwise unexplained hypoxemic
conditions.
Jodele et al. (73) report on five children after allogenic
HSCT with pulmonary arterial hypertension and clinical signs
of transplantation-associated thrombotic microangiopathy (TA-
TMA) with kidney injury. Cyclosporine was discontinued in
three of five patients and rituximab and PE showed no bene-
fit for another patient. The histology in three of them showed
global TMA in the pulmonary arterioles and cytomegalovirus
(CMV) and adenovirus could be detected in the lung tissue of
two patients. Interestingly, TA-TMA was found in 60% of patients
with hypoxemic respiratory failure after HSCT. No detailed com-
plement investigations were done for those patients. However,
Jodele et al. (74) reported CFH-Ab in 3/12 patients undergoing
HSCT. Antibodies were not detected in a control cohort consisting
of 18 patients after HSCT with no evidence for TMA. Homozy-
gous CFHR1 and three deletions were detected in three patients
further documenting the importance of complement deregula-
tion in HSCT TMA. In a recent guideline of HSCT TMA, TCC
activation was one of the most important factors for progno-
sis of the disease (75). Moreover, the efficacy of eculizumab
in several patients with HTCT TMA supports the importance
of complement-mediated mechanisms for this TMA entity and
thus for the role of complement-mediated TMA for pulmonary
hypertension (75, 76).
TMA AND THE GASTROINTESTINAL TRACT
Pancreatitis, intestinal bleeding and hepatic cytolysis are reported
mainly in patients with life-threatening multivisceral failure due
to diffuse TMA (5% of patients with aHUS) (1, 23, 24).
Diarrhea, especially bloody diarrhea as initial sign of entero-
hemorrhagic Escherichia coli enteritis/colitis is a “classical” presen-
tation of shigatoxin-HUS (41). On the other hand, diarrhea as
one important trigger factor for aHUS is nowadays well estab-
lished (1, 21, 77). However, addressing the question of intestinal
complement-mediated TMA involvement is highly difficult as only
a small number of representative case reports are available.
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A number of reports describe intestinal TMA in the context
of post-solid-organ transplant TMA possibly triggered/caused by
the use of calcineurin inhibitors (Cyclosporin A, Tacrolimus)
(78, 79). Intestinal TMA was diagnosed histologically. Patients
presented with abdominal colics, constipation, abdominal dis-
tension, strictures, occlusions, and even intestinal perforations
(78–80). For those patients, no complement analyses are docu-
mented. The important role of complement activation for dis-
ease pathogenesis in these patients is questionable considering
data of animal models provoking severe intestinal TMA induced
by intraperitoneal tacrolimus donation only (81). However,
no complement analyses were performed in those experiments
as well.
Similarly to solid organ transplantations intestinal TMA events
are reported in HSCT patients (80, 82). Again, no complement
analyses are available and thus the role of complement activation
for those events remains speculative.
Despite those reports, Ohanian et al. (27, 46) report on severe
neurological and intestinal involvement in a patient with comple-
ment activation on the basis of aHUS responsive to eculizumab
(genotyping is not reported). The 50-year-old female presented
with diarrhea and abdominal pain subsequently developing ful-
minant pancolitis with acute renal failure and thrombocytopenia.
Stool studies including EHEC were reported negative. Due to
the fulminant pancolitis, the patients underwent total abdominal
colectomy. The pathology confirmed ischemic colitis with features
of TMA.
Pancreas involvement in patients with HUS or TTP is reported
frequently (1, 21, 44, 83–85). Pancreatic ischemia caused by
HUS/TTP may contribute to the common symptom of abdom-
inal pain. The pathophysiology of development of pancreati-
tis is unknown, thus, TMA processes provoking intrapancreatic
endothelial cell damage remain speculative explanations. Inter-
estingly, it was hypothesized that pancreatitis may immediately
precede an acute episode of HUS/TTP and may serve as trig-
ger for TMA onset/recurrence (84, 85). It is suggested that the
acute inflammatory response to pancreatitis, mediated by TNF-
alpha, IL-1, IL-6, and IL-8 and further cytokines as well as the
circulating pancreatic proteases may lead to endothelial activa-
tion, endothelial cell damage, activation of intravasal coagula-
tion, and vWF-release and those mediating and aggravating TMA
processes on the basis of potential predispositions (including
complement-regulatory defects) (84, 85).
Pancreas involvement may lead to significant beta cell dysfunc-
tion with the development of insulin-dependent diabetes mellitus
(IDDM) in rare cases even years after HUS onset (1, 83, 86).
Geerdink et al. (21) reported on pancreas involvement at dis-
ease onset in 2/45 aHUS patients. One patient presented with a
necrotizing pancreatitis and developed IDDM 10 years thereafter.
It is speculated that a microangiopathic intrapancreatic process
is responsible for tissue ischemia with the potential involvement
of beta cells. Interestingly, beta cell dysfunction was reported for
3–15% of patients with shigatoxin-HUS (87). No complement
analyses are available for these reports.
Transaminasemia at disease onset is reported for 13/27 (44) and
79/138 (43) patients with CFH-Ab HUS as well as 41/108 patients
with HUS not further specified (43).
TMA AND THE SCELETAL MUSCLES
Rhabdomyolysis is reported in exceptional cases of TMA, mainly
in the context of multiorgan failure (86, 88). It is suggested that
rhabdomyolysis in those cases is caused by generalized muscle
ischemia resulting from the microangiopathic process in muscle
arterioles and capillaries (86). Reports on response to PE ther-
apy and recurrence of TMA and rhabdomyolysis after weaning
of PE support the causative role of the TMA process for the
rhabdomyolysis (86, 88).
Micheletti et al. (89) report on a male patient with HUS onset
at the age of 12 days. The initial HUS episode resolved with-
out specific therapy and without sequelae. During follow-up, a
steady increase in creatinine kinase (CK) and liver enzymes was
observed, thus a standard protocol for evaluation of neuromuscu-
lar diseases was initiated without significant findings. At the age
of 2 years following an acute febrile illness, the child developed
a HUS recurrence with decreased C3 levels and rhabdomyolysis.
After improvement of renal function and rhabdomyolysis on HD
and regular FFP infusions, there were several episodes of hemolysis
with an increase in CK over 2 months, thereafter full recovery of the
HUS recurrence was achieved, but CK and liver enzymes remained
above normal values. Complement and mitochondrial studies
revealed CFH-gene risk polymorphisms on the one hand and a
succinate coenzyme Q reductase (complex II) deficiency on the
other hand. During the following 3 years on treatment with ubide-
carenone, riboflavin, and carnitine, the child did not experience
further HUS recurrences and no further rhabdomyolysis.
Pena et al. (86) report on a 28-month-old girl with acute
onset of HUS and rhabdomyolysis, associated with pancreatic
involvement and IDDM.
Andreoli et al. (88) explain rhabdomyolysis episodes in HUS
patients as extra-renal TMA manifestations.
Saunier et al. (90) report on an infant with two episodes of rhab-
domyolysis associated with HUS at 3 and 6 months of age. Investi-
gations showed extremely reduced cytochrome c oxidase/succinate
cytochrome c reductase ratio.
AUTOIMMUNITY AND TMA
Complement activation leading to TMA also occurs on the back-
ground of diverse autoimmune/connective tissue disorders (2). In
systemic lupus erythematosus (SLE), the complement system is
known to play an important role in the pathogenesis of disease,
especially in the development of lupus nephritis (91). Immune
complex mediated complement activation leads to C4d deposition
on endothelial cells and might correlate with the development of
TMA in lupus nephritis (92, 93). Not only the activation of the
CP, but also the activation of LP and AP seem to play a role in
the development of TMA (94). One study reports TMA lesions
in 24% of 148 renal biopsies of Chinese lupus nephritis patients,
many of them also presenting decreased CFH levels in plasma
(95). Furthermore, variants of genes encoding CFHR1 and 3 may
contribute to the development of SLE (96). Those homozygous
deletions are related to CFH-Ab production in aHUS (42, 45), in
addition these antibodies were detected in 6.7% of 60 Swedish SLE
patients (97).
The antiphospholipid syndrome (APS) is characterized by arte-
rial and venous thrombi and most frequently occurs in association
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with other autoimmune diseases, most commonly with SLE (in
addition and independently of lupus nephritis) (98). Comple-
ment activation through antiphospholipid antibodies may also be
involved in the development of TMA in the APS. This relationship
has been shown in murine models (99), and one unique article
reports on the success of eculizumab treatment in three patients
with APS nephropathy (100).
In the antineutrophil cytoplasmatic autoantibodies (ANCA) –
associated vasculitis (AAV), the endothelium is damaged through
oxygen reactive species and proteolytic enzymes released by
ANCA-bound neutrophils. In addition, neutrophils release prop-
erdin and CFB, which activate the AP that might lead to TMA.
One recent review summarizes the reports on the coexistence of
AAV and TMA (2).
Thrombotic microangiopathies also could play a role in the
pathogenesis of further connective tissue diseases, especially in the
renal involvement, such as systemic sclerodermia (101), Sjögrens
Syndrome (102).
ANA positivity was reported in 7/27 patients with CFH-Ab
HUS (Titer 1:80–1:1250; speckled pattern) (44).
A better knowledge about the role of complement and devel-
opment of TMA in autoimmune and connective tissue diseases
could serve as a rationale for the use of complement directed thera-
pies in those disease entities. However, physicians treating patients
with those disorders should be aware of possible TMA events and
manifestations.
DISCUSSION
The excess in complement activation due to the inherited or
acquired disorders of complement regulation is associated with
significant thrombophilia (5, 103). Complement activation dis-
rupts endothelial cell integrity and the physiologically thrombore-
sistent endothelial phenotype, thus contributing to thrombotic
occlusions in the micro- and even macro-vasculature (4, 5, 20,
103). Endothelial surface C3b deposition recruits white cells into
the area of endothelial damage (3–5, 20, 103). In addition, stressed
endothelial cells express P-selectines and further adhesion proteins
leading to release of vWf and platelet aggregation (5, 20, 104).
Complement-mediated damage of thrombocytes was shown to
induce the expression of the inflammatory CD40 ligand, further
amplifying a pro-inflammatory milieu at site of endothelial cell
damage and thus the vasculature (104). The microangiopathic
thrombotic lesions lead to mechanic hemolysis and free heme
induces further C3b deposition with further promotion of C5a
production and TCC insertion on endothelial cells (105). Interest-
ingly, studies in paroxysmal–nocturnal–hemoglobinuria (PNH)
and aHUS have shown that complement inhibition through
eculizumab was able to significantly reduce markers of hemosta-
tic activation (D-Dimer), endothelial activation [soluble vascular
cell adhesion protein 1 (sVCAM-1)], and inflammation [soluble
tumor-necrosis-factor 1 (sTNFR1)] (5).
As endothelial dysfunction due to multiple risk factors is a
more random explanation for TMA pathogenesis, one has to
question its interpretation on the basis of the above presented
data. Extra-renal side effects are mainly reported for complement-
mediated TMA forms; interestingly, in patients treated withVEGF-
blockers, one study documented a high number of localized
renal TMA events with or without hematologic signs of HUS
(106), but no patients with further extra-renal manifestations
strengthen our hypothesis that severe extra-renal TMA on the
basis of endothelial dysfunction is additionally dependent on a
complement-regulatory defect.
The presented cases lead to the assumption that despite the
absence of overt disease recurrences and even in the setting of nor-
mal laboratory basic evaluations progression of extra-renal (and
indeed renal) vascular lesions is possible and striking under certain
circumstances, especially in the setting of high risk mutations in
combination with long-term dialysis. Thus, it is the uncontrolled,
subclinic, systemic complement activation, and dysregulation that
cause inflammation and endothelial damage leading to renal and
extra-renal manifestations on the basis of a thrombotic micro-
and/or “macro”-angiopathy.
The important role of complement activation for vascular
stenosis in general is documented in several studies, although
the detailed mechanisms are still unclear (107, 108). Moreover,
complement activation is present in human and experimental
arteriosclerosis and TCC deposition correlates with disease state
(107, 108). As already detailed above, complement activation leads
to endothelial up regulation of adhesion molecules and release
of leukotrienes and further cytokines, which concert leukocyte
recruitment, activation, and transmigration together with the high
potential chemotaxines C3a and C5a (4, 5, 20, 103). All these
events cause vessel wall inflammation, further endothelial dam-
age, vessel obstruction, and through release of platelet-derived-
growth-factor (PDGF) vessel wall thickening and stenosis (4,
5, 20, 103). Of importance, most reported cases with vascular
stenosis were on dialysis and hemodialysis filters were shown to
induce complement activation. Thus, complement activation due
to HD procedures could exacerbate in the setting of complement-
regulatory defects and further contribute to advanced endothelial
and vascular damage.
Reminiscing the different case summaries on extra-renal TMA
manifestations detailed above, one can easily recognize the dif-
ferent levels of evidence concerning complement activation and
deregulation for the presented patients. Especially for neurovas-
cular, cardiovascular, and peripheral vascular and skin manifesta-
tions, the summarized evidence strongly supports a crucial role of
complement activation and deregulation for the development of
TMA and “macroangiopathies.”
Considering pulmonary and gastrointestinal involvement, the
differentiation of directly complement-mediated TMA induced
injury and secondary therapy and infection induced phenomena
is more speculative, although clear evidence exists that comple-
ment triggered TMA can directly induce pulmonary hypertension
and hemorrhage as well as distinctive gastrointestinal symptoms
in some patients with mainly very severe TMA.
Physicians have to be aware of secondary TMA phenomena
in patients with autoimmune disorders involving endothelial cells
like SLE, APA syndrome, and AAV.
Of note, extra-renal complement-mediated TMA manifesta-
tions occur either in an acute setting at disease onset or under
recurrences or as late manifestations of an continuous and smol-
dering complement activation process on the basis of regulatory
defects in addition to potential TMA triggers like infections, CNI,
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radiation, etc. Especially, macrovascular lesions seem to progress
even during symptom-free intervals, especially in patients with
high risk mutations and ongoing HD.
These facts may stimulate the discussion on the prophylactic
use of eculizumab to potentially prevent serious complement-
mediated vascular damage especially for high risk patients on HD
(CFH, CFB, CFI mutations, and CFH-Ab patients). Still the deci-
sion on how and when to use and wean eculizumab has to be
decided on an individual basis considering renal and extra-renal
perspectives in combination with the underlying pathophysiology
of the affected patient.
The treating physician has to be aware of those possible extra-
renal manifestations even despite disease acute phase and to
initiate an appropriate monitoring of these patients (authors rec-
ommendation: see Figure 2). In general, the treating physician has
to raise his awareness for extra-renal complement-mediated TMA
processes with mild to severe manifestations in nearly all organ
systems to be able to introduce individualized diagnostic work up
and therapeutic interventions.
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